For instance, in clear cell renal cell carcinoma (ccRCC), elevated ROS production activates the MAPK signaling pathway, leading to the overexpression of matrix metalloproteinase-2 (MMP2), a protease responsible for degrading ECM components. This evidence concerns the gene MMP2 and nonpapillary renal cell carcinoma.